MPM BioImpact’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-319,670
| Closed | -$3.63M | – | 44 |
|
|
2023
Q4 | $3.63M | Hold |
319,670
| – | – | 0.85% | 28 |
|
|
2023
Q3 | $1.29M | Sell |
319,670
-1
| -0% | -$7 | 0.34% | 32 |
|
|
2023
Q2 | $2.27M | Hold |
319,671
| – | – | 0.46% | 31 |
|
|
2023
Q1 | $2.38M | Hold |
319,671
| – | – | 0.62% | 26 |
|
|
2022
Q4 | $2.32M | Hold |
319,671
| – | – | 0.6% | 26 |
|
|
2022
Q3 | $3.1M | Hold |
319,671
| – | – | 0.73% | 25 |
|
|
2022
Q2 | $6.11M | Hold |
319,671
| – | – | 1.7% | 17 |
|
|
2022
Q1 | $15.9M | Hold |
319,671
| – | – | 4.26% | 5 |
|
|
2021
Q4 | $24.1M | Hold |
319,671
| – | – | 4.4% | 7 |
|
|
2021
Q3 | $25.3M | Hold |
319,671
| – | – | 3.92% | 7 |
|
|
2021
Q2 | $44.3M | Sell |
319,671
-70,171
| -18% | -$13.4M | 7.28% | 5 |
|
|
2021
Q1 | $81.6M | Hold |
389,842
| – | – | 10.25% | 2 |
|
|
2020
Q4 | $64.8M | Hold |
389,842
| – | – | 11.37% | 5 |
|
|
2020
Q3 | $66.2M | Hold |
389,842
| – | – | 15.96% | 3 |
|
|
2020
Q2 | $64.7M | Hold |
389,842
| – | – | 17.21% | 2 |
|
|
2020
Q1 | $45.1M | Hold |
389,842
| – | – | 27.58% | 1 |
|
|
2019
Q4 | $57.7M | Buy |
+389,842
| New | +$59.1M | 20.43% | 1 |
|
MPM BioImpact's HARP Position: Q1 2024 in Review
MPM BioImpact sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 319,670 shares — an estimated $3.63M sold.
MPM BioImpact first reported a position in HARP in Q4 2019 and held it in 17 quarters. The position peaked at $81.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- MPM BioImpact reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- MPM BioImpact sold 319,670 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.63M.
- MPM BioImpact first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- MPM BioImpact's Harpoon Therapeutics, Inc. Common Stock position peaked at $81.6M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.